pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Xyosted
drug
save

testosterone enanthate

Marketedupdated 3mo ago
by Antares Pharma Inc
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying testosterone enanthate

  • phase2Working Out M0 Bipolar Androgen Therapyrecruitingn=69
  • phase352 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadismrecruitingn=100
  • phase2Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancercompletedn=36
  • phase4Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosisnot yet recruitingn=20

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 4, 2026
53 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (69)

  • Aug 30, 2038formulationUS 10646495
  • Aug 30, 2038formulationUS 10646495
  • Aug 30, 2038formulationUS 10646495
  • Sep 4, 2036formulationUS 9950125
  • Sep 4, 2036formulationUS 9950125
  • Sep 4, 2036formulationUS 9950125
  • Nov 19, 2035formulationUS 9744302
  • Nov 19, 2035formulationUS 9744302
  • Nov 19, 2035formulationUS 9744302
  • Oct 18, 2035formulationUS 11191908
  • Oct 18, 2035formulationUS 11191908
  • Oct 18, 2035formulationUS 11191908
  • Feb 25, 2035formulationUS 11813435
  • Feb 25, 2035formulationUS 11813435
  • Feb 25, 2035formulationUS 11813435
  • Feb 19, 2035formulationUS 10238662
  • Feb 19, 2035formulationUS 10238662
  • Feb 19, 2035formulationUS 10238662
  • Feb 19, 2035formulationUS 10912782
  • Feb 19, 2035formulationUS 10912782
  • Feb 19, 2035formulationUS 10912782
  • Oct 7, 2034formulationUS 11160751
  • Oct 7, 2034formulationUS 11160751
  • Oct 7, 2034formulationUS 11160751
  • Feb 11, 2034formulationUS 10881798
  • Feb 11, 2034formulationUS 10881798
  • Feb 11, 2034formulationUS 10881798
  • Jun 4, 2033formulationUS 10821072
  • Jun 4, 2033formulationUS 10821072
  • Jun 4, 2033formulationUS 10821072
  • Jun 4, 2033method-of-use (U-2418)US 11844804
  • Jun 4, 2033method-of-use (U-2418)US 11844804
  • Jun 4, 2033method-of-use (U-2418)US 11844804
  • Aug 21, 2031formulationUS 10357609
  • Aug 21, 2031formulationUS 10357609
  • Aug 21, 2031formulationUS 10357609
  • Aug 21, 2031formulationUS 10905827
  • Aug 21, 2031formulationUS 10905827
  • Aug 21, 2031formulationUS 10905827
  • Aug 21, 2031formulationUS 11446440
  • Aug 21, 2031formulationUS 11446440
  • Aug 21, 2031formulationUS 11446440
  • Jul 31, 2031formulationUS 102791315.0y
  • Jul 31, 2031formulationUS 102791315.0y
  • Jul 31, 2031formulationUS 102791315.0y
  • Mar 19, 2030formulationUS 114977533.6y
  • Mar 19, 2030formulationUS 114977533.6y
  • Mar 19, 2030formulationUS 114977533.6y
  • Oct 4, 2026formulationUS 802133553d
  • Oct 4, 2026formulationUS 802133553d
  • Oct 4, 2026formulationUS 802133553d
  • Jan 24, 2026formulationUS 10478560
  • Jan 24, 2026formulationUS 10478560
  • Jan 24, 2026formulationUS 10478560
  • Jan 24, 2026formulationUS 11446441
  • Jan 24, 2026formulationUS 11446441
  • Jan 24, 2026formulationUS 11446441
  • Jan 24, 2026formulationUS 8562564
  • Jan 24, 2026formulationUS 8562564
  • Jan 24, 2026formulationUS 8562564
  • Jan 24, 2026formulationUS 9180259
  • Jan 24, 2026formulationUS 9180259
  • Jan 24, 2026formulationUS 9180259
  • Jan 24, 2026formulationUS 9533102
  • Jan 24, 2026formulationUS 9533102
  • Jan 24, 2026formulationUS 9533102
  • Jan 24, 2026formulationUS 9629959
  • Jan 24, 2026formulationUS 9629959
  • Jan 24, 2026formulationUS 9629959

News(0)

no news has mentioned this drug yet

brand
Xyosted
generic
testosterone enanthate
indication
Secondary (Hypogonadotropic) Hypogonadism
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 6m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?